<DOC>
	<DOCNO>NCT03011996</DOCNO>
	<brief_summary>Cohort 1 To evaluate pharmacokinetic interaction CJ-12420 multiple oral dos CJ-12420 give alone combination amoxicillin/clarithromycin healthy subject . Cohort 2 To evaluate pharmacodynamic profile CJ-12420 multiple oral dos CJ-12420 combination amoxicillin/clarithromycin healthy subject compare active control group , i.e. , pantoprazole combination amoxicillin/clarithromycin .</brief_summary>
	<brief_title>To Investigate PK PD CJ-12420 , Clarithromycin , Amoxicillin After Multiple Dose Administration</brief_title>
	<detailed_description>To evaluate pharmacokinetic drug-drug interaction CJ-12420 amoxicillin/clarithromycin investigate pharmacodynamic co-administration CJ-12420 amoxicillin clarithromycin .</detailed_description>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>1 . Healthy male volunteer age ≥19 ≤45 year screen ; 2 . No congenital chronic disease , morbid symptom finding screen test ; 3 . Body mass index ( BMI ) ≥18.5 ≤28 kg/m2 ; 4 . Considered eligible base medical examination ( include interview , vital sign , 12lead ECG , physical exam laboratory test ) set perform accordance nature investigational product investigator ; 5 . Voluntary consent participate study fully inform purpose procedure study , profile investigational product prior participation ; 6 . For Cohort 2 , positive 13C urea breath test . 1 . Medical history 1 . History current evidence disease consider clinically relevant investigator include hepatic , renal , gastrointestinal , respiratory , musculoskeletal , endocrine , neurologic , hematooncological , urinary , cardiovascular ( include cardiac arrhythmia ) diseases ; 2 . History gastrointestinal disease ( gastritis , gastrodynia , gastroesophageal reflux disease , Crohn 's disease ulcer ) abdominal surgery ( except simple appendectomy herniotomy ) consider potential effect drug absorption investigator ; 3 . For Cohort 2 , previous treatment failure H. pylorus eradication . 2 . Laboratory test ECG 1 . AST ALT ≥ 1.25 x upper limit normal ( ULN ) ; 2 . Total bilirubin ≥ 1.5 x ULN ; 3. eGFR calculate CKDEPI formula &lt; 80 mL/min ; 4 . Any clinically relevant ECG abnormality . 3 . Allergy drug abuse 1 . History hypersensitivity drug contain investigational product ( penicillin , cephems , macrolides , pantoprazole benzimidazole ) drug ( include aspirin antibiotic ) ; 2 . History drug abuse positive drug screen test . 4 . Drug/dietary restriction 1 . Medications ( include herbal supplement ) abnormal diet ( e.g. , grapefruit juice &gt; 1 L/day , excessive garlic , broccoli , kale , etc . ) may effect absorption , distribution , metabolism excretion investigational product within 28 day prior first study dose ; 2 . Use prescription drug , overthecounter drug ( OTCs ) vitamins within 10 day prior first study dose ; 3 . Participating study receive investigational product within 3 month prior first study dose . 5 . Blood donation transfusion 1 . Whole blood donation within 60 day prior first study dose ; 2 . Donation blood component transfusion within 30 day prior first study dose . 6 . Pregnancy contraception 1 . Pregnant breastfeeding ; 2 . Subject partner 's inability use medically qualify dualcontraceptive method medically acceptable contraception ( include intrauterine device establish pregnancy failure rate , barrier method spermicide , vasectomy , tubectomy , tubal ligation hysterectomy ) screen 30 day last dose investigational product . 7 . Others 1 . Heavy use alcohol ( average alcohol intake ≥30 g/day ) positive alcohol test ; 2 . Heavy smoker ( &gt; 10 cigarettes/day ) ; 3 . Caffeine intake &gt; 400 mg/day ; 4 . Any clinically relevant finding consider inappropriate study participation discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>